Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label guselkumab study in moderately to severely active Crohn's disease
jRCT2080225202Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of guselkumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started May 2020; status: completed.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2080225202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225202.